JP4845730B2 - Ppar活性化合物 - Google Patents
Ppar活性化合物 Download PDFInfo
- Publication number
- JP4845730B2 JP4845730B2 JP2006520413A JP2006520413A JP4845730B2 JP 4845730 B2 JP4845730 B2 JP 4845730B2 JP 2006520413 A JP2006520413 A JP 2006520413A JP 2006520413 A JP2006520413 A JP 2006520413A JP 4845730 B2 JP4845730 B2 JP 4845730B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- methoxy
- indol
- propionic acid
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 COc1ccc2N(Cc3c(*=C(F)F)cccc3)CC(CCC(O)=O)c2c1 Chemical compound COc1ccc2N(Cc3c(*=C(F)F)cccc3)CC(CCC(O)=O)c2c1 0.000 description 10
- YTXPXSDMTWDDNZ-UHFFFAOYSA-N CC(C)(Cc(c1c2)c[n](CS(c3ccc(C)c(C)c3)(=O)=O)c1ccc2OC)C(O)=O Chemical compound CC(C)(Cc(c1c2)c[n](CS(c3ccc(C)c(C)c3)(=O)=O)c1ccc2OC)C(O)=O YTXPXSDMTWDDNZ-UHFFFAOYSA-N 0.000 description 1
- CTVVTXOUSRFRDH-UHFFFAOYSA-M CCCCOc(cc1)ccc1S(N(CC(CCC(O)=O)c1c2)c1ccc2OC)([O-])=O Chemical compound CCCCOc(cc1)ccc1S(N(CC(CCC(O)=O)c1c2)c1ccc2OC)([O-])=O CTVVTXOUSRFRDH-UHFFFAOYSA-M 0.000 description 1
- OOGOHVSGCZRHBM-UHFFFAOYSA-N CCCCc(cc1)ccc1S([n](cc(CCC(O)=O)c1c2)c1ccc2OCC)(=O)=O Chemical compound CCCCc(cc1)ccc1S([n](cc(CCC(O)=O)c1c2)c1ccc2OCC)(=O)=O OOGOHVSGCZRHBM-UHFFFAOYSA-N 0.000 description 1
- RASVABVRTHPERH-KPKJPENVSA-N CCCCc(cc1)ccc1[S+]([n](cc(/C=C/C(O)=O)c1c2)c1ccc2O)(=O)=O Chemical compound CCCCc(cc1)ccc1[S+]([n](cc(/C=C/C(O)=O)c1c2)c1ccc2O)(=O)=O RASVABVRTHPERH-KPKJPENVSA-N 0.000 description 1
- NIXYFOIIQNYYQD-UHFFFAOYSA-O COC(CC(C1)c2cc(OC)ccc2N1O[SH+](c1cc(C(F)(F)F)ccc1)=O)=O Chemical compound COC(CC(C1)c2cc(OC)ccc2N1O[SH+](c1cc(C(F)(F)F)ccc1)=O)=O NIXYFOIIQNYYQD-UHFFFAOYSA-O 0.000 description 1
- KPUHNJKSYNQXOJ-UHFFFAOYSA-N COC(CCC(C1)c2cc(OC)ccc2N1S(c(cc1)ccc1OC(F)(F)F)(=O)=O)=O Chemical compound COC(CCC(C1)c2cc(OC)ccc2N1S(c(cc1)ccc1OC(F)(F)F)(=O)=O)=O KPUHNJKSYNQXOJ-UHFFFAOYSA-N 0.000 description 1
- VFJHGTNRJVDFPN-UHFFFAOYSA-N COC(CCc(c1cc(OC)ccc11)c[n]1[S+](c1ccccc1)(=O)=O)=O Chemical compound COC(CCc(c1cc(OC)ccc11)c[n]1[S+](c1ccccc1)(=O)=O)=O VFJHGTNRJVDFPN-UHFFFAOYSA-N 0.000 description 1
- ZLAXOYLATANQBF-UHFFFAOYSA-N COc(cc1c(CCC(O)=O)c2)ccc1[n]2S(c(cc1)ccc1OCc(cc1)ccc1C(N)=O)(=O)=O Chemical compound COc(cc1c(CCC(O)=O)c2)ccc1[n]2S(c(cc1)ccc1OCc(cc1)ccc1C(N)=O)(=O)=O ZLAXOYLATANQBF-UHFFFAOYSA-N 0.000 description 1
- TWNRHTGRKGELJX-UHFFFAOYSA-N COc(cc1c(CCC(O)=O)c2)ccc1[n]2S(c1cc(OC)cc(OC)c1)(=O)=O Chemical compound COc(cc1c(CCC(O)=O)c2)ccc1[n]2S(c1cc(OC)cc(OC)c1)(=O)=O TWNRHTGRKGELJX-UHFFFAOYSA-N 0.000 description 1
- VSQNAALSRGYGDU-UHFFFAOYSA-N COc(cc1c(CCC(O)=O)c2)ccc1[n]2[SH+2](c(cc1)ccc1Oc1ccccc1)[OH2+] Chemical compound COc(cc1c(CCC(O)=O)c2)ccc1[n]2[SH+2](c(cc1)ccc1Oc1ccccc1)[OH2+] VSQNAALSRGYGDU-UHFFFAOYSA-N 0.000 description 1
- XMUOBORGBZEPMJ-UHFFFAOYSA-N COc(cc1c(CCC(O)=O)c2)ccc1[n]2[SH-](c(cc1)ccc1Cl)(=O)=O Chemical compound COc(cc1c(CCC(O)=O)c2)ccc1[n]2[SH-](c(cc1)ccc1Cl)(=O)=O XMUOBORGBZEPMJ-UHFFFAOYSA-N 0.000 description 1
- BSQBFMPFTLGUND-UHFFFAOYSA-N COc1ccc2N(Cc(cc3)ccc3Cl)CC(CCC(O)=O)c2c1 Chemical compound COc1ccc2N(Cc(cc3)ccc3Cl)CC(CCC(O)=O)c2c1 BSQBFMPFTLGUND-UHFFFAOYSA-N 0.000 description 1
- SLWWSHZXUMFUTA-UHFFFAOYSA-P COc1ccc2[n](C[S+](c(cc3)ccc3OC(F)(F)F)(O)=O)cc(CCC(O)=O)c2c1 Chemical compound COc1ccc2[n](C[S+](c(cc3)ccc3OC(F)(F)F)(O)=O)cc(CCC(O)=O)c2c1 SLWWSHZXUMFUTA-UHFFFAOYSA-P 0.000 description 1
- KCXGAZDTVSBIKS-UHFFFAOYSA-N COc1ccc2[n](Cc(cc3)ccc3F)cc(CCC(O)=O)c2c1 Chemical compound COc1ccc2[n](Cc(cc3)ccc3F)cc(CCC(O)=O)c2c1 KCXGAZDTVSBIKS-UHFFFAOYSA-N 0.000 description 1
- BLHXORFATJZTEP-UHFFFAOYSA-N COc1cnc2[nH]cc(C=O)c2c1 Chemical compound COc1cnc2[nH]cc(C=O)c2c1 BLHXORFATJZTEP-UHFFFAOYSA-N 0.000 description 1
- XNRIKINNKULMGN-UHFFFAOYSA-N COc1ncc(C(CCC(O)=O)CN2)c2c1 Chemical compound COc1ncc(C(CCC(O)=O)CN2)c2c1 XNRIKINNKULMGN-UHFFFAOYSA-N 0.000 description 1
- QSNMCLKISUKAHU-UHFFFAOYSA-N COc1ncc(CCN2)c2c1 Chemical compound COc1ncc(CCN2)c2c1 QSNMCLKISUKAHU-UHFFFAOYSA-N 0.000 description 1
- IWLFWGLFINYFHA-UHFFFAOYSA-N Cc([nH]1)cc2c1ncc(Br)c2 Chemical compound Cc([nH]1)cc2c1ncc(Br)c2 IWLFWGLFINYFHA-UHFFFAOYSA-N 0.000 description 1
- XDHFUUVUHNOJEW-UHFFFAOYSA-N Cc([nH]1)cc2c1nccc2 Chemical compound Cc([nH]1)cc2c1nccc2 XDHFUUVUHNOJEW-UHFFFAOYSA-N 0.000 description 1
- VAACICAUORHETR-UHFFFAOYSA-N Cc1cc2cc(OC)cnc2[nH]1 Chemical compound Cc1cc2cc(OC)cnc2[nH]1 VAACICAUORHETR-UHFFFAOYSA-N 0.000 description 1
- FWBFTBYLTUNVFC-UHFFFAOYSA-O Cc1cccc([SH+](O[n](cc(CC(OC)=O)c2c3)c2ccc3OC)=O)c1 Chemical compound Cc1cccc([SH+](O[n](cc(CC(OC)=O)c2c3)c2ccc3OC)=O)c1 FWBFTBYLTUNVFC-UHFFFAOYSA-O 0.000 description 1
- HUFACZWVOQSGOJ-UHFFFAOYSA-N O=C1NC=C(CCN2)C2=C1 Chemical compound O=C1NC=C(CCN2)C2=C1 HUFACZWVOQSGOJ-UHFFFAOYSA-N 0.000 description 1
- FNJNGJLJWJWHSM-UHFFFAOYSA-N OC(CCc(c1cc(-c2c[s]cc2)ccc11)c[n]1S(c1ccccc1)(=O)=O)=O Chemical compound OC(CCc(c1cc(-c2c[s]cc2)ccc11)c[n]1S(c1ccccc1)(=O)=O)=O FNJNGJLJWJWHSM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48852303P | 2003-07-17 | 2003-07-17 | |
US60/488,523 | 2003-07-17 | ||
US55299404P | 2004-03-12 | 2004-03-12 | |
US60/552,994 | 2004-03-12 | ||
PCT/US2004/023234 WO2005009958A1 (en) | 2003-07-17 | 2004-07-16 | Ppar active compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007534625A JP2007534625A (ja) | 2007-11-29 |
JP4845730B2 true JP4845730B2 (ja) | 2011-12-28 |
Family
ID=34107772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006520413A Active JP4845730B2 (ja) | 2003-07-17 | 2004-07-16 | Ppar活性化合物 |
Country Status (18)
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8603949B2 (en) * | 2003-06-17 | 2013-12-10 | California Institute Of Technology | Libraries of optimized cytochrome P450 enzymes and the optimized P450 enzymes |
KR20130023381A (ko) | 2003-07-17 | 2013-03-07 | 플렉시콘, 인코퍼레이티드 | Ppar 활성 화합물 |
US7348338B2 (en) * | 2003-07-17 | 2008-03-25 | Plexxikon, Inc. | PPAR active compounds |
WO2005026193A2 (en) * | 2003-09-08 | 2005-03-24 | United States Army Medical Research And Materiel Command | Small molecules and a pharmacophore model for inhibition of botulinum toxin and methods of making and using thereof |
PE20060303A1 (es) | 2004-06-23 | 2006-05-19 | Wyeth Corp | Metabolitos de indolilalquilamina como ligandos de 5-hidroxitriptamina-6 |
US7531568B2 (en) | 2004-11-30 | 2009-05-12 | Plexxikon, Inc. | PPAR active compounds |
EP1833787A2 (en) * | 2004-11-30 | 2007-09-19 | Plexxikon, Inc. | Indole derivatives for use as ppar active compounds |
WO2007010965A1 (ja) * | 2005-07-22 | 2007-01-25 | Shionogi & Co., Ltd. | Pgd2受容体アンタゴニスト活性を有するアザインドール酸誘導体 |
FR2890071B1 (fr) * | 2005-08-30 | 2007-11-09 | Fournier Sa Sa Lab | Nouveaux composes de l'indole |
FR2890072A1 (fr) | 2005-09-01 | 2007-03-02 | Fournier S A Sa Lab | Nouveaux composesde pyrrolopyridine |
CA2621474A1 (en) * | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | 1,3-disubstituted indole derivatives for use as ppar modulators |
EP1931658A2 (en) * | 2005-09-07 | 2008-06-18 | Plexxikon, Inc. | 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds |
KR20080042170A (ko) * | 2005-09-07 | 2008-05-14 | 플렉시콘, 인코퍼레이티드 | Ppar 활성 화합물 |
JP5093096B2 (ja) | 2006-03-02 | 2012-12-05 | アステラス製薬株式会社 | 17βHSDtype5阻害剤 |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
PE20090159A1 (es) * | 2007-03-08 | 2009-02-21 | Plexxikon Inc | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs |
JP5671236B2 (ja) | 2007-03-14 | 2015-02-18 | ランバクシー ラボラトリーズ リミテッド | ホスホジエステラーゼ阻害剤としてのピラゾロ(3,4−b)ピリジン誘導体 |
BRPI0814423B1 (pt) | 2007-07-17 | 2022-04-19 | Plexxikon, Inc | Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos |
JP2011513331A (ja) * | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | ピラゾール[3,4−b]ピリジンRAF阻害剤 |
WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
FR2942964B1 (fr) | 2009-03-16 | 2012-08-17 | Arkopharma Laboratoires | Stimulateur metabolique des ppaps a base d'esters d'acides gras libres insatures, composition huileuse et complement alimentaire les contenant |
NZ595789A (en) | 2009-04-29 | 2014-05-30 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
US20100317706A1 (en) * | 2009-04-30 | 2010-12-16 | Bumham Institute For Medical Research | HNF4alpha MODULATORS AND METHODS OF USE |
US20100286220A1 (en) * | 2009-04-30 | 2010-11-11 | Burnham Institute For Medical Research | HNF4alpha ANTAGONISTS AND METHODS OF USE |
AU2010321883A1 (en) | 2009-11-18 | 2012-05-31 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
BR112012015745A2 (pt) | 2009-12-23 | 2016-05-17 | Plexxikon Inc | compostos e métodos para a modulação de quinase, e indicações dos mesmos |
FR2955110A1 (fr) | 2010-01-08 | 2011-07-15 | Fournier Lab Sa | Nouveaux derives de type pyrrolopyridine benzoique |
FR2955108B1 (fr) | 2010-01-08 | 2012-03-16 | Fournier Lab Sa | Utilisation de derives de pyrrolopyridine comme activateurs de nurr-1, pour le traitement de la maladie de parkinson |
TWI619713B (zh) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | 用於激酶調節的化合物和方法及其適應症 |
RS62051B1 (sr) | 2010-08-18 | 2021-07-30 | Biosplice Therapeutics Inc | Diketoni i hidroksiketoni kao aktivatori katenin signalnog puta |
BR112013020041B1 (pt) | 2011-02-07 | 2021-11-23 | Plexxikon, Inc | Compostos e composições para a modulação de quinases e uso dos mesmos |
BR112013029163A2 (pt) | 2011-05-17 | 2017-01-31 | Plexxikon Inc | modulação quinase e indicações dos mesmos |
WO2012178142A1 (en) * | 2011-06-23 | 2012-12-27 | Metabolic Solutions Development Company, Llc | Ppar-sparing compounds and combinations fort the treatment of diabetes and other metabolic diseases |
EP2768499A4 (en) | 2011-10-17 | 2015-08-26 | Univ Vanderbilt | INDOMETACIN ANALOGUES FOR THE TREATMENT OF CANCER PROSTATE RESISTANT TO CASTRATION |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
AU2013259624B2 (en) * | 2012-05-08 | 2017-10-19 | Lycera Corporation | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease |
EP2892534B8 (en) | 2012-09-06 | 2021-09-15 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
SG11201504754QA (en) | 2012-12-21 | 2015-07-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
SI2968249T1 (sl) | 2013-02-22 | 2019-04-30 | Samumed, Llc | Gama-diketoni kot aktivatorji signalne poti Wnt/beta-katenin |
PL2970265T3 (pl) | 2013-03-15 | 2018-11-30 | Plexxikon Inc. | Heterocykliczne związki i ich zastosowania |
US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
EP3004060B1 (en) | 2013-05-30 | 2019-11-27 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
KR102129842B1 (ko) * | 2013-10-02 | 2020-07-06 | 주식회사 대웅제약 | 술포닐인돌 유도체 및 이의 제조방법 |
WO2015134536A1 (en) | 2014-03-04 | 2015-09-11 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
CA2949163A1 (en) | 2014-05-14 | 2015-11-19 | The Regents Of The University Of Colorado, A Body Corporate | Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof |
HUE046741T2 (hu) | 2014-08-20 | 2020-03-30 | Samumed Llc | Gamma-diketonok bõröregedés és ráncok megelõzésére és kezelésére |
ES2774177T3 (es) | 2014-09-15 | 2020-07-17 | Plexxikon Inc | Compuestos heterocíclicos y usos de estos |
US10160755B2 (en) | 2015-04-08 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
JP6946194B2 (ja) | 2015-05-06 | 2021-10-06 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼを調節する化合物の固体形態 |
HUE047657T2 (hu) | 2015-05-06 | 2020-05-28 | Plexxikon Inc | Kináz-moduláló hatású 1H-pirrolo[2,3-b]piridin származékok szintézise |
US10829484B2 (en) | 2015-07-28 | 2020-11-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
CA2999253C (en) | 2015-09-21 | 2021-10-26 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
ITUB20153978A1 (it) * | 2015-09-28 | 2017-03-28 | Laboratorio Chimico Int S P A | Procedimento per la preparazione di derivati di indanammina e di nuovi intermedi di sintesi. |
WO2017100201A1 (en) | 2015-12-07 | 2017-06-15 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US10160747B2 (en) | 2016-03-16 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US10660334B2 (en) | 2016-08-15 | 2020-05-26 | Bayer Cropscience Aktiengesellschaft | Fused bicyclic heterocycle derivatives as pesticides |
TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ido及tdo調節之化合物及方法以及其適應症 |
JP7193460B2 (ja) | 2016-12-23 | 2022-12-20 | プレキシコン インコーポレーテッド | Cdk8調節およびその適応症のための化合物および方法 |
ES2896502T3 (es) | 2017-03-20 | 2022-02-24 | Plexxikon Inc | Formas cristalinas de ácido 4-(1-(1,1-di(piridin-2-il) etil)-6-(3,5-dimetilisoxazol-4-il)-1H-pirrolo[3,2-b]piridin-3- il)benzoico que inhiben el bromodominio |
WO2018226846A1 (en) | 2017-06-07 | 2018-12-13 | Plexxikon Inc. | Compounds and methods for kinase modulation |
CA3070505C (en) | 2017-07-25 | 2023-09-26 | Plexxikon Inc. | Formulations of a compound modulating kinases |
CA3079029A1 (en) | 2017-10-13 | 2019-04-18 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
TWI803530B (zh) | 2017-10-27 | 2023-06-01 | 美商普雷辛肯公司 | 調節激酶之化合物之調配物 |
CA3094336A1 (en) | 2018-03-20 | 2019-09-26 | Plexxikon Inc. | Compounds and methods for ido and tdo modulation, and indications therefor |
BR112021019957A2 (pt) | 2019-04-09 | 2021-12-07 | Plexxikon Inc | Azinas condensadas para modulação de ep300 ou cbp e indicações da mesma |
AU2021261383A1 (en) | 2020-04-23 | 2022-11-17 | Opna Bio SA | Compounds and methods for CD73 modulation and indications therefor |
CN116322690A (zh) | 2020-08-21 | 2023-06-23 | 奥普纳生物有限公司 | 组合的药物抗癌疗法 |
CN115504925B (zh) * | 2021-06-22 | 2024-03-12 | 广东药科大学 | 一类ppar激动剂、其制备方法及其作为药物的用途 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB957990A (en) * | 1961-03-14 | 1964-05-13 | Merck & Co Inc | Salts of substituted indoles |
JPH0710838A (ja) * | 1993-04-16 | 1995-01-13 | Eli Lilly & Co | sPLA2阻害剤1H−インドール−3−酢酸ヒドラジド |
WO1996037469A1 (en) * | 1995-05-22 | 1996-11-28 | Merck Frosst Canada Inc. | N-benzylindol-3-yl propanic acid derivatives as cyclooxygenase-2 inhibitors |
WO2000029022A1 (en) * | 1998-11-12 | 2000-05-25 | Algos Pharmaceutical Corporation | Cox-2 inhibitors in combination with centrally acting analgesics |
JP2000226373A (ja) * | 1998-04-08 | 2000-08-15 | Takeda Chem Ind Ltd | アミン誘導体、その製造法および剤 |
JP2002538078A (ja) * | 1998-11-12 | 2002-11-12 | アルゴス ファーマシューティカル コーポレーション | 痛みを治療するnmda−ブロッカーと組み合わされたcox−2阻害剤 |
WO2003018553A1 (en) * | 2001-08-29 | 2003-03-06 | Warner-Lambert Company Llc | Oral antidiabetic agents |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1482844A (fr) | 1964-12-31 | 1967-06-02 | Merck & Co Inc | Procédé de préparation de nouveaux acides 2-[2-(phénylalkyl substitué)-3-indolyl] aliphatiques inférieurs |
US3489767A (en) * | 1966-01-12 | 1970-01-13 | Sumitomo Chemical Co | 1-(phenylsulfonyl)-3-indolyl aliphatic acid derivatives |
US3511841A (en) * | 1967-05-29 | 1970-05-12 | Sterling Drug Inc | 1-((4-,5-,6-,and 7-azaindolyl)-lower-alkyl)- 4-substituted-piperazines |
GB1573212A (en) | 1976-04-15 | 1980-08-20 | Technicon Instr | Immunoassay for gentamicin |
US4568649A (en) | 1983-02-22 | 1986-02-04 | Immunex Corporation | Immediate ligand detection assay |
US4626513A (en) | 1983-11-10 | 1986-12-02 | Massachusetts General Hospital | Method and apparatus for ligand detection |
EP0154734B1 (en) | 1984-03-15 | 1990-08-29 | Immunex Corporation | Immediate ligand detection assay, a test kit and its formation |
US5688655A (en) | 1988-02-10 | 1997-11-18 | Ict Pharmaceuticals, Inc. | Method of screening for protein inhibitors and activators |
US5283251A (en) | 1990-02-26 | 1994-02-01 | Fujisawa Pharmaceutical Co., Ltd. | Indole derivatives |
GB9004301D0 (en) * | 1990-02-26 | 1990-04-18 | Fujisawa Pharmaceutical Co | Indolebutyric acid derivatives and process for preparation thereof |
US5075313A (en) * | 1990-09-13 | 1991-12-24 | Eli Lilly And Company | 3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof |
US5466689A (en) * | 1993-02-08 | 1995-11-14 | Takeda Chemical Industries, Ltd. | Morpholine derivatives and their use |
US5840485A (en) | 1993-05-27 | 1998-11-24 | Selectide Corporation | Topologically segregated, encoded solid phase libraries |
AU686186B2 (en) | 1993-05-27 | 1998-02-05 | Aventisub Ii Inc. | Topologically segregated, encoded solid phase libraries |
US5763198A (en) | 1994-07-22 | 1998-06-09 | Sugen, Inc. | Screening assays for compounds |
GB9416467D0 (en) * | 1994-08-13 | 1994-10-05 | Wellcome Found | Compounds for use in medicine |
US5747276A (en) | 1995-09-15 | 1998-05-05 | The Scripps Research Institute | Screening methods for the identification of novel antibiotics |
US6294330B1 (en) | 1997-01-31 | 2001-09-25 | Odyssey Pharmaceuticals Inc. | Protein fragment complementation assays for the detection of biological or drug interactions |
US6243980B1 (en) | 1997-03-07 | 2001-06-12 | Tropix, Inc. | Protease inhibitor assay |
US6178384B1 (en) | 1997-09-29 | 2001-01-23 | The Trustees Of Columbia University In The City Of New York | Method and apparatus for selecting a molecule based on conformational free energy |
US6337344B1 (en) | 1997-12-24 | 2002-01-08 | Aventis Pharma Deutschland Gmbh | Indole derivatives as inhibitors or factor Xa |
DE69932414T2 (de) * | 1998-02-23 | 2007-02-22 | South Alabama Medical Science Foundation, Mobile | Indol-3-propionsäure, salze und ester davon als arzneimittel # |
CA2327695A1 (en) * | 1998-04-08 | 1999-10-21 | Takeda Chemical Industries, Ltd. | Amine compounds, their production and their use as somatostatin receptor antagonists or agonists |
EP1085846A2 (en) | 1998-06-08 | 2001-03-28 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
DE60035682T2 (de) * | 1999-04-28 | 2008-04-30 | Sanofi-Aventis Deutschland Gmbh | Di-aryl-säurederivate als ppar rezeptor liganden |
ATE323678T1 (de) | 1999-04-28 | 2006-05-15 | Aventis Pharma Gmbh | Tri-aryl-säurederivate als ppar rezeptor liganden |
DE60025621T2 (de) | 1999-09-17 | 2006-11-23 | Kyorin Pharmaceutical Co., Ltd. | O-anisamid-derivate |
FR2801585B1 (fr) * | 1999-11-25 | 2002-02-15 | Fournier Ind & Sante | Nouveaux antagonistes des recepteurs de l'ii-8 |
HUP0203895A3 (en) | 1999-12-24 | 2004-09-28 | Aventis Pharma Ltd West Mallin | Substituted azaindoles and pharmaceutical compositions containing them and their use |
ES2312432T3 (es) | 2000-05-29 | 2009-03-01 | Kyorin Pharmaceutical Co., Ltd. | Derivados del acido fenilpropionico sustituidos. |
DE10046029A1 (de) | 2000-09-18 | 2002-03-28 | Bayer Ag | Indazole |
US6858640B2 (en) * | 2000-09-22 | 2005-02-22 | Shionogi & Co., Ltd. | Tricyclic indole compounds having affinity for serotonin receptor |
CA2425121A1 (en) | 2000-10-11 | 2002-04-18 | Esperion Therapeutics, Inc. | Ether compounds and compositions for cholesterol management and related uses |
KR100959356B1 (ko) * | 2001-06-12 | 2010-05-20 | 웰스테트 테라퓨틱스 코포레이션 | 대사 질환의 치료용 화합물 |
US6806265B2 (en) | 2002-05-16 | 2004-10-19 | Boehringer Ingelheim International Gmbh | Non-nucleoside reverse transcriptase inhibitors |
JPWO2004007439A1 (ja) | 2002-07-10 | 2005-11-10 | 住友製薬株式会社 | ビアリール誘導体 |
SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
EP1578716A1 (en) | 2002-12-20 | 2005-09-28 | Novo Nordisk A/S | Dicarboxylic acid derivatives as ppar-agonists |
ES2351624T3 (es) | 2003-05-06 | 2011-02-08 | Ústav Experimentálni Botaniky Av Cr, V.V.I. (Institute Of Experimental Botany Academy Of Sciences Of The Czech Republic, Pro) | Pirazolo[4,3-d]pirimidinas, procedimiento para su preparación y uso. |
US7348338B2 (en) * | 2003-07-17 | 2008-03-25 | Plexxikon, Inc. | PPAR active compounds |
KR20130023381A (ko) | 2003-07-17 | 2013-03-07 | 플렉시콘, 인코퍼레이티드 | Ppar 활성 화합물 |
WO2005012221A1 (ja) | 2003-08-04 | 2005-02-10 | Ono Pharmaceutical Co., Ltd. | ジフェニルエーテル化合物、その製造方法および用途 |
WO2005040112A1 (en) * | 2003-10-14 | 2005-05-06 | Oxagen Limited | Compounds with pgd2 antagonist activity |
US7608639B2 (en) | 2003-10-14 | 2009-10-27 | Eli Lilly And Company | Phenoxyether derivatives as PPAR modulators |
GB2407318A (en) * | 2003-10-23 | 2005-04-27 | Oxagen Ltd | Substituted Indol-3-yl acetic acid derivatives |
GB0324886D0 (en) | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
DE602004011985T2 (de) | 2003-11-25 | 2009-03-05 | Eli Lilly And Co., Indianapolis | Modulatoren des peroxisomproliferatoraktivierten rezeptors |
-
2004
- 2004-07-16 KR KR1020137002335A patent/KR20130023381A/ko not_active Application Discontinuation
- 2004-07-16 JP JP2006520413A patent/JP4845730B2/ja active Active
- 2004-07-16 DK DK04778641.3T patent/DK1648867T3/da active
- 2004-07-16 WO PCT/US2004/023234 patent/WO2005009958A1/en active Application Filing
- 2004-07-16 CA CA002532403A patent/CA2532403A1/en not_active Abandoned
- 2004-07-16 US US10/893,134 patent/US7202266B2/en active Active
- 2004-07-16 KR KR1020067001015A patent/KR101415503B1/ko not_active IP Right Cessation
- 2004-07-16 RU RU2006100920/04A patent/RU2356889C2/ru not_active IP Right Cessation
- 2004-07-16 NZ NZ545326A patent/NZ545326A/en not_active IP Right Cessation
- 2004-07-16 BR BRPI0412684-0A patent/BRPI0412684A/pt not_active IP Right Cessation
- 2004-07-16 CN CN2012103274659A patent/CN102875441A/zh active Pending
- 2004-07-16 EP EP04778641.3A patent/EP1648867B1/en active Active
- 2004-07-16 UA UAA200600453A patent/UA88767C2/uk unknown
- 2004-07-16 AU AU2004259738A patent/AU2004259738B2/en active Active
-
2006
- 2006-01-11 IL IL173079A patent/IL173079A/en not_active IP Right Cessation
- 2006-01-16 EC EC6288A patent/ECSP066288A/es unknown
- 2006-01-17 CR CR8194A patent/CR8194A/es unknown
- 2006-01-24 NO NO20060385A patent/NO20060385L/no not_active Application Discontinuation
- 2006-07-21 HK HK06108153.0A patent/HK1086010A1/xx not_active IP Right Cessation
-
2007
- 2007-02-27 US US11/679,738 patent/US7723374B2/en active Active
- 2007-02-27 US US11/679,777 patent/US7491831B2/en active Active
- 2007-02-27 US US11/679,792 patent/US7476746B2/en active Active
-
2010
- 2010-04-28 US US12/768,729 patent/US8367828B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB957990A (en) * | 1961-03-14 | 1964-05-13 | Merck & Co Inc | Salts of substituted indoles |
JPH0710838A (ja) * | 1993-04-16 | 1995-01-13 | Eli Lilly & Co | sPLA2阻害剤1H−インドール−3−酢酸ヒドラジド |
WO1996037469A1 (en) * | 1995-05-22 | 1996-11-28 | Merck Frosst Canada Inc. | N-benzylindol-3-yl propanic acid derivatives as cyclooxygenase-2 inhibitors |
JP2000226373A (ja) * | 1998-04-08 | 2000-08-15 | Takeda Chem Ind Ltd | アミン誘導体、その製造法および剤 |
WO2000029022A1 (en) * | 1998-11-12 | 2000-05-25 | Algos Pharmaceutical Corporation | Cox-2 inhibitors in combination with centrally acting analgesics |
JP2002538078A (ja) * | 1998-11-12 | 2002-11-12 | アルゴス ファーマシューティカル コーポレーション | 痛みを治療するnmda−ブロッカーと組み合わされたcox−2阻害剤 |
WO2003018553A1 (en) * | 2001-08-29 | 2003-03-06 | Warner-Lambert Company Llc | Oral antidiabetic agents |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4845730B2 (ja) | Ppar活性化合物 | |
US7348338B2 (en) | PPAR active compounds | |
US7605168B2 (en) | PDE4B inhibitors | |
JP5138938B2 (ja) | Ret調節剤の開発のための化合物および方法 | |
US20070066641A1 (en) | Compounds and methods for development of RET modulators | |
US7498342B2 (en) | Compounds modulating c-kit activity | |
AU2005265017A1 (en) | Azaindoles modulating c-kit activity and uses therefor | |
WO2006078287A9 (en) | Pde4b inhibitors and uses therefor | |
JP2008521831A (ja) | Ppar活性化合物 | |
MXPA06000624A (en) | Ppar active compounds | |
TW200536527A (en) | PPAR active compounds | |
Guo | Hot Spot-Based Design and Synthesis of Small Molecule Inhibitors for β-Catenin/T-Cell Factor 4 Protein-Protein Interaction and Hemiporphyrin-Like N2-Acyl 2-Aminoimidazoles: Chemistry, Biology and Zinc Binding Properties |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20100728 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100824 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101122 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110223 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110405 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110805 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110808 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20110824 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110913 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111011 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141021 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4845730 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |